News
Hunt Regional Medical Center Improves Patient Experience with Vocera
Hospital reports 13 percent increase in HCAHPS after deploying leader rounding and care call technology SAN JOSE, Calif. January 4, 2018 –(BUSINESS WIRE)– Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, today announced that Hunt Regional Medical Center has improved patient engagement and satisfaction by standardizing nurse leader rounding and […]
Hospital Sisters Health System Selects Health Catalyst Data Operating System to Support Outcomes Improvement
SPRINGFIELD, IL., and SALT LAKE CITY, January 3, 2018 – Health Catalyst, a technology leader in healthcare analytics, decision support and outcomes improvement, announced a multi-year agreement with Hospital Sisters Health System to implement the Health Catalyst Data Operating System (DOS™). Hospital Sisters Health System (HSHS) is a multi-institutional health care system that cares for […]
U.S. Army Regional Health Command-Pacific Expands Vocera Technology at Three Facilities
$2.8 million contract caps record year of federal bookings for Vocera SAN JOSE, Calif. January 3, 2018 –(BUSINESS WIRE)– Vocera Communications, Inc. (NYSE:VCRA), a recognized leader in clinical communication and workflow solutions, announced today that U.S. Army Regional Health Command-Pacific (RHC-P) is expanding Vocera technology at three military facilities. This $2.8 million contract completes a […]
Health Share of Oregon and Health Catalyst Expand Program for Behavioral Health Analytics, Improved Quality and Cost
Coordinated care network co-develops opioid risk-prediction tool; adopts Data Operating System PORTLAND, OR. and SALT LAKE CITY – December 19, 2017 – In an effort to further enhance quality and lower the cost of health care, Health Share of Oregon and Health Catalyst have expanded their partnership through the implementation of a data-first application platform […]
Alkermes Initiates Rolling Submission of ALKS 5461 New Drug Application for Major Depressive Disorder
Company Expects to Complete Submission for Fast Track Designated Medicine by Year-End 2017 DUBLIN–(BUSINESS WIRE)–Aug. 21, 2017– Alkermes plc (NASDAQ:ALKS) today announced the initiation of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), seeking marketing approval of ALKS 5461, a once-daily, oral investigational medicine with a […]
Alkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia
Once-Daily, Oral Product Candidate Demonstrated Antipsychotic Efficacy Statistically Superior to Placebo and Similar to Olanzapine in ENLIGHTEN-1 Study Management to Hold Conference Call Today at 4:30 p.m. ET DUBLIN–(BUSINESS WIRE)–Jun. 29, 2017– Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from ENLIGHTEN-1, the first of two key phase 3 studies in the ENLIGHTEN […]
Alkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
Phase 3b Study Designed to Further Evaluate ALKS 5461’s Potential Benefits on Mood Domains Regulated by Endogenous Opioid Modulation Company Reiterates Plans to Submit New Drug Application to FDA by Year-End 2017 DUBLIN–(BUSINESS WIRE)–Jun. 12, 2017– Alkermes plc (NASDAQ: ALKS) today announced the initiation of study 217, a phase 3b trial of ALKS 5461, a […]
Alkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients
Designed to Assess Weight Gain Profile of Olanzapine Compared to ALKS 3831 in Patients Diagnosed With Schizophrenia, Schizophreniform or Bipolar I Disorder Who Are Early in Their Illness Supportive Study in the ENLIGHTEN Clinical Development Program for ALKS 3831, an Investigational, Novel, Once-Daily, Oral Atypical Antipsychotic for the Treatment of Schizophrenia DUBLIN–(BUSINESS WIRE)–Jun. 8, 2017– […]
FDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia
First and Only Long-Acting Atypical Antipsychotic With Two-Month Dosing Option Approval Expands ARISTADA’s Product Offerings to Include Once-Monthly, Once-Every-Six-Weeks and Once-Every-Two-Months Dosing Durations DUBLIN–(BUSINESS WIRE)–Jun. 6, 2017– Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. […]
Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia
Once-Daily, Oral Product Candidate Showed Efficacy Equivalent to Olanzapine With Clinically Meaningful and Statistically Significant Lower Weight Gain in 300-Patient Study Company Plans to Initiate Pivotal Development Program in 2015 DUBLIN–(BUSINESS WIRE)–Jan. 7, 2015– Alkermes plc (NASDAQ: ALKS) today announced positive topline results from the 12-week, randomized, double-blind, active-controlled, dose-ranging stage of a phase 2 […]